Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of the National Cancer Institute

• Publication date

  1993-01-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/85.1.53PMID 7677935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of p53 and 17p allelic loss in colorectal carcinoma.

  1992cited by this paper
• High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx.

  1992cited by this paper
• Frequent association of p53 gene mutation in invasive bladder cancer.

  1992cited by this paper
• Overexpression and mutation of p53 in epithelial ovarian cancer.

  1991cited by this paper
• The p53 tumour suppressor gene

  1991cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder.

  1991cited by this paper
• Identification of p53 gene mutations in bladder cancers and urine samples.

  1991cited by this paper
• The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif.

  1990cited by this paper
• Increased expression of mutant forms of p53 oncogene in primary lung cancer.

  1990cited by this paper
• Should pT1 transitional cell cancers of the bladder still be classified as superficial?

  1988cited by this paper
• Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life

  1988cited by this paper
• Radical cystectomy--often too late?

  1987cited by this paper
• Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract.

  1987cited by this paper
• Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

  1986cited by this paper
• The significance of lamina propria invasion on the prognosis of patients with bladder tumors.

  1980cited by this paper
• T1 bladder tumours.

  1977cited by this paper

• Tumor profiling of advanced urothelial carcinoma: Comparative analysis based on social determinants of health.

  2025cites this paper
• Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification

  2024cites this paper
• Proliferation and immunohistochemistry for p53, CD25 and CK20 in predicting prognosis of non-muscle invasive papillary urothelial carcinomas

  2024cites this paper
• The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder

  2023cites this paper
• The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta‐analysis

  2021cites this paper
• Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project.

  2021cites this paper
• Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight

  2021cites this paper
• Flat Urothelial Lesions

  2021cites this paper
• Role and efficacy of current biomarkers in bladder cancer

  2020cites this paper
• Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy

  2019cites this paper
• Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology

  2019cites this paper
• Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway

  2019influential citation
• Prognostic significance of p16 immunohistochemical expression in urothelial carcinoma

  2019cites this paper
• Aspects of Development and Progression of Bladder Cancer 2

  2019cites this paper
• 2 Molecular Pathways of Bladder Cancer Development and Progression

  2018cites this paper
• Molecular Prognostication in Bladder Cancer.

  2018cites this paper
• Stem Cell Oncology

  2018cites this paper
• Risk Factors and Molecular Features Associated with Bladder Cancer Development

  2018cites this paper
• Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood

  2018cites this paper
• Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy

  2018influential citation
• Significance of Ki-67 in non-muscle invasive bladder cancer patients: a systematic review and meta-analysis

  2017cites this paper
• Non-invasive detection of bladder cancer through the analysis of driver gene mutations and aneuploidy

  2017influential citation
• Non-invasive detection of upper tract urothelial carcinomas through the analysis of driver gene mutations and aneuploidy in urine

  2017cites this paper
• Metastasis : The Interaction of Cancer and Its Host Environment

  2017cites this paper
• Differential metallothionein isoform expression as biomarkers of cadmium exposure in human urothelium

  2017cites this paper
• Cancer Genetics, Cancer Biology, and Tumor Growth and Metastasis

  2017cites this paper
• Non-invasive detection of bladder cancer through the analysis of driver gene 1 mutations and aneuploidy 2 3

  2017cites this paper
• Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder

  2017cites this paper
• Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example

  2016cites this paper
• The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN

  2016cites this paper
• p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis

  2016cites this paper
• The Emerging Molecular Landscape of Urothelial Carcinoma.

  2016cites this paper
• Molecular substratification of bladder cancer: moving towards individualized patient management

  2016cites this paper
• Research progress of oncogene and tumor suppressor gene in bladder cancer.

  2015cites this paper
• Bladder cancer: molecular determinants of personalized therapy.

  2015cites this paper
• Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?

  2015cites this paper
• Impact of p 53 , MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis

  2015cites this paper
• Epidemiology, Pathology, Aetiological Factors, Prevention, Screening, Symptoms, and Signs

  2015cites this paper
• Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer

  2015cites this paper
• CD 10 expression in urothelial carcinoma of the bladder

  2015cites this paper
• Non-muscle invasive bladder cancer risk stratification

  2015influential citation
• Endothelial Growth Factor and Survivin in Patients with Bladder Cancer

  2015cites this paper
• CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer

  2015cites this paper
• Present and future of personalized medicine in adult genitourinary tumors.

  2015cites this paper
• Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

  2015cites this paper
• New and promising strategies in the management of bladder cancer.

  2015cites this paper
• Emerging concepts on drug resistance in bladder cancer: Implications for future strategies.

  2015cites this paper
• The development of pre-clinical models to study and identify novel biomarkers in muscle invasive bladder cancer

  2015influential citation
• Clinical Utility of Altered Expressions of P53,Vascular Endothelial Growth Factor and Survivin in Patients with Bladder Cancer

  2015cites this paper
• Whole exome sequencing of Urothelial Bladder Cancer: identification of ARID1A and STAG2 as new, important, players

  2014cites this paper
• Centrosome Amplification as Biomarkers in Bladder Cancer Using Touch Biopsy and Bladder Washing Cytological Specimens

  2014cites this paper
• Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis.

  2014cites this paper
• Impact of p53, MIB-1 and PECAM-1 expression on the prognosis of urothelial carcinoma of the renal pelvis.

  2014cites this paper
• Biomarkers in bladder cancer: translational and clinical implications.

  2014cites this paper
• Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy

  2014cites this paper
• Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?

  2014cites this paper
• Interleukin-20 Promotes Migration of Bladder Cancer Cells through Extracellular Signal-regulated Kinase (ERK)-mediated MMP-9 Protein Expression Leading to Nuclear Factor (NF-B) Activation by Inducing the

  2013cites this paper
• THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.

  2013cites this paper
• Recurrence of high‐risk bladder cancer: A population‐based analysis

  2013cites this paper
• TP53 mutations in myelodysplastic syndromes with deletion of 5q

  2013cites this paper
• Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: involvement of the p21WAF1 expression.

  2013cites this paper
• Prognostic value of p53 protein overexpression in upper tract urothelial carcinomas in Taiwan.

  2013cites this paper
• Metastasis After Primary Treatment — Peri-Operative and Bladder-Preservation Therapy in Muscle Invasive Diseases

  2013cites this paper
• Clinical Applications of Recent Molecular Advances in Urologic Malignancies: No Longer Chasing a “Mirage”?

  2013cites this paper
• Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat.

  2013cites this paper
• Centrosome amplification in bladder washing cytology specimens is a useful prognostic biomarker for non-muscle invasive bladder cancer.

  2013cites this paper
• Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression.

  2013cites this paper
• Chromosomal imbalances in successive moments of human bladder urothelial carcinoma.

  2013cites this paper
• Prognostic Factors Including Ki-67 and p53 in Bacillus Calmette-Guérin-Treated Non-Muscle-Invasive Bladder Cancer: A Prospective Study

  2013cites this paper
• Transitional Cell Carcinoma of the Bladder

  2013cites this paper
• Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.

  2013cites this paper
• Molecular genetics and genomics progress in urothelial bladder cancer.

  2013cites this paper
• p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells

  2012cites this paper
• Tissue‐based Biomarkers

  2012cites this paper
• Molecular Pathogenesis of Bladder Cancer

  2012cites this paper
• Emerging critical role of molecular testing in diagnostic genitourinary pathology.

  2012cites this paper
• Effects of P-MAPA Immunomodulator on Toll-Like Receptors and p53: Potential Therapeutic Strategies for Infectious Diseases and Cancer

  2012cites this paper
• Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

  2012cites this paper
• Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

  2012cites this paper
• Aspekte des Harnblasenkarzinoms

  2012cites this paper
• A study of p53 expression in transitional cell carcinoma of urinary bladder in Erbil governorate

  2012cites this paper
• Selected common diagnostic problems in urologic pathology: perspectives from a large consult service in genitourinary pathology.

  2012cites this paper
• Molecular Pathology of Bladder Cancer.

  2012cites this paper
• Progress in Personalizing Chemotherapy for Bladder Cancer

  2012cites this paper
• Normal and neoplastic urothelial stem cells: getting to the root of the problem

  2012cites this paper
• Interleukin-20 Promotes Migration of Bladder Cancer Cells through Extracellular Signal-regulated Kinase (ERK)-mediated MMP-9 Protein Expression Leading to Nuclear Factor (NF-κB) Activation by Inducing the Up-regulation of p21WAF1 Protein Expression*

  2012cites this paper
• Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.

  2012cites this paper
• Molecular Genetics and Cancer Biology

  2012cites this paper
• Molecular diagnostics in urologic malignancies: a work in progress.

  2011cites this paper
• TP53 - molecular soldier's mutations in bladder cancer in the Kashmiri population.

  2011influential citation
• Assessment of Phytochemicals in Preventing Oxidatively Damaged DNA in Bladder Cancer

  2011cites this paper
• Molecular markers and bladder carcinoma: Schistosomal and non-schistosomal.

  2011cites this paper
• Bladder: transitional cell carcinoma

  2011cites this paper
• Mesane Kanseri Gelişiminde Moleküler Mekanizmaların Rolü

  2011cites this paper
• Chapter 16 – Immunohistology of the Prostate, Bladder, Kidney, and Testis

  2011cites this paper
• Role of Tumor Suppressor and Angiogenesis Markers in Prediction of Recurrence of Non Muscle Invasive Bladder Cancer

  2011cites this paper
• PRACTICAL & CONTROVERSIAL ISSUES IN DIAGNOSIS , GRADING AND STAGING OF UROTHELIAL CARCINOMA : AN APPROACH

  2011cites this paper
• A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53

  2011cites this paper
• Mesane Kanseri Gelişiminde Moleküler Mekanizmalarin Rolü

  2011cites this paper
• Desmocollin 2 is a new immunohistochemical marker indicative of squamous differentiation in urothelial carcinoma

  2011cites this paper